Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri

C. C. Coddington, R. L. Collins, T. H. Shawker, R. Anderson, Donald (Lynn) Loriaux, C. A. Winkel

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Because the size of leiomyomata uteri often decreases significantly after menopause, the authors elected to employ a long-acting gonadotropin hormone-releasing hormone analog (GnRH-a) (imbzl-D-His6-Pro9-Net-GnRH) to create a state of pseudomenopause in six patients with leiomyomata uteri diagnosed on the basis of pelvic examination and confirmed by pelvic ultrasonography. Patients received daily, subcutaneous injections of GnRH-a (4 μg x kg-1 x 24 hour-1) for 6 months. Uterine size (13.8 ± 4 weeks [mean ± standard deviation (SD), n = 6] was determined by pelvic examination and uterine volume (533.9 ± 394 ml [mean ± SD, n = 6]) was determined by pelvic ultrasonography before medical therapy was begun. They observed a decrease in uterine size by pelvic examination within 4 weeks of the initiation of therapy, and all patients experienced a decrease in uterine size (9.5 ± 4 weeks [mean ± SD, n = 6]) (P-1 throughout the period of therapy. All six patients have discontinued therapy. There has been no increase in uterine size in these patients for a period from 3 to 7 months. The authors conclude that administration of a long-acting GnRH-a appears to be a practical method for reducing the size of uterine leiomyomata and may serve a useful role either as a primary means of therapy or as an adjunct to surgical myomectomy, especially in patients with exceedingly large myomas who wish to conserve reproductive capability.

Original languageEnglish (US)
Pages (from-to)624-629
Number of pages6
JournalFertility and Sterility
Volume45
Issue number5
StatePublished - 1986
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Uterus
Hormones
Gynecological Examination
Leiomyoma
Uterine Myomectomy
Ultrasonography
Therapeutics
Myoma
Subcutaneous Injections
Menopause

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Coddington, C. C., Collins, R. L., Shawker, T. H., Anderson, R., Loriaux, D. L., & Winkel, C. A. (1986). Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertility and Sterility, 45(5), 624-629.

Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. / Coddington, C. C.; Collins, R. L.; Shawker, T. H.; Anderson, R.; Loriaux, Donald (Lynn); Winkel, C. A.

In: Fertility and Sterility, Vol. 45, No. 5, 1986, p. 624-629.

Research output: Contribution to journalArticle

Coddington, CC, Collins, RL, Shawker, TH, Anderson, R, Loriaux, DL & Winkel, CA 1986, 'Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri', Fertility and Sterility, vol. 45, no. 5, pp. 624-629.
Coddington CC, Collins RL, Shawker TH, Anderson R, Loriaux DL, Winkel CA. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertility and Sterility. 1986;45(5):624-629.
Coddington, C. C. ; Collins, R. L. ; Shawker, T. H. ; Anderson, R. ; Loriaux, Donald (Lynn) ; Winkel, C. A. / Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. In: Fertility and Sterility. 1986 ; Vol. 45, No. 5. pp. 624-629.
@article{9f9697d31b3d49ceac5a1b59f5e0d05e,
title = "Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri",
abstract = "Because the size of leiomyomata uteri often decreases significantly after menopause, the authors elected to employ a long-acting gonadotropin hormone-releasing hormone analog (GnRH-a) (imbzl-D-His6-Pro9-Net-GnRH) to create a state of pseudomenopause in six patients with leiomyomata uteri diagnosed on the basis of pelvic examination and confirmed by pelvic ultrasonography. Patients received daily, subcutaneous injections of GnRH-a (4 μg x kg-1 x 24 hour-1) for 6 months. Uterine size (13.8 ± 4 weeks [mean ± standard deviation (SD), n = 6] was determined by pelvic examination and uterine volume (533.9 ± 394 ml [mean ± SD, n = 6]) was determined by pelvic ultrasonography before medical therapy was begun. They observed a decrease in uterine size by pelvic examination within 4 weeks of the initiation of therapy, and all patients experienced a decrease in uterine size (9.5 ± 4 weeks [mean ± SD, n = 6]) (P-1 throughout the period of therapy. All six patients have discontinued therapy. There has been no increase in uterine size in these patients for a period from 3 to 7 months. The authors conclude that administration of a long-acting GnRH-a appears to be a practical method for reducing the size of uterine leiomyomata and may serve a useful role either as a primary means of therapy or as an adjunct to surgical myomectomy, especially in patients with exceedingly large myomas who wish to conserve reproductive capability.",
author = "Coddington, {C. C.} and Collins, {R. L.} and Shawker, {T. H.} and R. Anderson and Loriaux, {Donald (Lynn)} and Winkel, {C. A.}",
year = "1986",
language = "English (US)",
volume = "45",
pages = "624--629",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri

AU - Coddington, C. C.

AU - Collins, R. L.

AU - Shawker, T. H.

AU - Anderson, R.

AU - Loriaux, Donald (Lynn)

AU - Winkel, C. A.

PY - 1986

Y1 - 1986

N2 - Because the size of leiomyomata uteri often decreases significantly after menopause, the authors elected to employ a long-acting gonadotropin hormone-releasing hormone analog (GnRH-a) (imbzl-D-His6-Pro9-Net-GnRH) to create a state of pseudomenopause in six patients with leiomyomata uteri diagnosed on the basis of pelvic examination and confirmed by pelvic ultrasonography. Patients received daily, subcutaneous injections of GnRH-a (4 μg x kg-1 x 24 hour-1) for 6 months. Uterine size (13.8 ± 4 weeks [mean ± standard deviation (SD), n = 6] was determined by pelvic examination and uterine volume (533.9 ± 394 ml [mean ± SD, n = 6]) was determined by pelvic ultrasonography before medical therapy was begun. They observed a decrease in uterine size by pelvic examination within 4 weeks of the initiation of therapy, and all patients experienced a decrease in uterine size (9.5 ± 4 weeks [mean ± SD, n = 6]) (P-1 throughout the period of therapy. All six patients have discontinued therapy. There has been no increase in uterine size in these patients for a period from 3 to 7 months. The authors conclude that administration of a long-acting GnRH-a appears to be a practical method for reducing the size of uterine leiomyomata and may serve a useful role either as a primary means of therapy or as an adjunct to surgical myomectomy, especially in patients with exceedingly large myomas who wish to conserve reproductive capability.

AB - Because the size of leiomyomata uteri often decreases significantly after menopause, the authors elected to employ a long-acting gonadotropin hormone-releasing hormone analog (GnRH-a) (imbzl-D-His6-Pro9-Net-GnRH) to create a state of pseudomenopause in six patients with leiomyomata uteri diagnosed on the basis of pelvic examination and confirmed by pelvic ultrasonography. Patients received daily, subcutaneous injections of GnRH-a (4 μg x kg-1 x 24 hour-1) for 6 months. Uterine size (13.8 ± 4 weeks [mean ± standard deviation (SD), n = 6] was determined by pelvic examination and uterine volume (533.9 ± 394 ml [mean ± SD, n = 6]) was determined by pelvic ultrasonography before medical therapy was begun. They observed a decrease in uterine size by pelvic examination within 4 weeks of the initiation of therapy, and all patients experienced a decrease in uterine size (9.5 ± 4 weeks [mean ± SD, n = 6]) (P-1 throughout the period of therapy. All six patients have discontinued therapy. There has been no increase in uterine size in these patients for a period from 3 to 7 months. The authors conclude that administration of a long-acting GnRH-a appears to be a practical method for reducing the size of uterine leiomyomata and may serve a useful role either as a primary means of therapy or as an adjunct to surgical myomectomy, especially in patients with exceedingly large myomas who wish to conserve reproductive capability.

UR - http://www.scopus.com/inward/record.url?scp=0022574505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022574505&partnerID=8YFLogxK

M3 - Article

C2 - 3084300

AN - SCOPUS:0022574505

VL - 45

SP - 624

EP - 629

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -